The Boston Globe

Business

Boston.com

Genzyme plans to grow in Mass.

Local operations seen as a springboard into personalized medicine

By Robert Weisman

 |  Globe Staff  

  December 15, 2011

Drawing on resources from its new parent company, Genzyme Corp. plans to grow over time in Massachusetts and increasingly apply its business model to drugs that serve larger patient populations, its new chief executive said yesterday. Cambridge’s Genzyme, formerly the largest biotechnology company based in the state, was sold last April to French pharmaceutical giant Sanofi SA, in a $20.1 billion deal that set off alarms at Genzyme’s headquarters about the company’s future presence in Massachusetts.

Thank you for reading BostonGlobe.com. You have reached the monthly limit for free articles — to continue reading, get unlimited access to BostonGlobe.com now for just 99¢ for 8 weeks.

Unlimited access to BostonGlobe.com includes:

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
GET STARTED TODAY

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help